Emcyt: profile and news

/SECOND AND FINAL ADD -- NYTU041B -- Pfizer Inc Earnings/ Apr 19, 2005
FirstRESOURCE: Aromasin, Camptosar, Celebrex, Ellence, Emcyt, Idamycin, Trelstar, and Zinecard are made available to eligible low-income uninsured oncology ... - PR Newswire

Modified Taxotere® Regimen Effective for Advanced Prostate Cancer Feb 25, 2005
Researchers from Greece have reported that the treatment combination consisting of Taxotere® (docetaxel), estramustine (Emcyt®) and Zometa® (zoledronic acid ... - Cancer Consultants (press release),

Other information

Indication
For the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate

Pharmacology
Estramustine is an antineoplastic agent indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate. Estramustine is a combination of estradiol with nornitrogen mustard. The precise mechanism of action of estramustine is unknown. Unlike other alkylating agents, estramustine does not directly damage DNA.

Mechanism Of Action
The precise mechanism of action of estramustine is unknown.

Drug Category
Antineoplastic Agents; Antineoplastic Agents; Radiation-Protective Agents; ATC:L01XX11

Brand Names/Synonyms
Emcyt; Estracyt; Estramustin Sodium Phosphate; Estramustina [Inn-Spanish]; Estramustine; Estramustine Sodium Phosphate; Estramustine [Usan:Ban:Inn]; Estramustinum [Inn-Latin]; Leo 275

Dosage Forms
CAPSULE

Absorption
Not Available

Interactions
Interactions for Estramustine:

Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.

Chemical IUPAC Name
(17-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl)bis(2-chloroethyl)aminomethanoate

Chemical Formula
C23H31Cl2NO3

Half Life
20 hours

Drug Type
Approved Drug

# Accession No
APRD00625

CAS Registry Number
2998-57-4